PT  - JOURNAL ARTICLE
AU  - Anyaehie, Michelle N.
AU  - Pardo, Christian
AU  - Johnson, Elijah J
AU  - Anachebe, Chucks
AU  - Piper, Brian J.
TI  - Opioid distribution trends in California post recreational marijuana legalization
AID  - 10.1101/2021.02.20.21252025
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.20.21252025
4099  - http://medrxiv.org/content/early/2021/03/03/2021.02.20.21252025.short
4100  - http://medrxiv.org/content/early/2021/03/03/2021.02.20.21252025.full
AB  - The opioid epidemic has risen to an all-time high. Harm reduction and prevention policies have not alleviated this crisis. Recent investigations have highlighted the efficacy and safety of marijuana-based products for pain management. Providing alternative pain treatment options may help mitigate the opioid epidemic. The distribution of codeine, fentanyl, hydrocodone, morphine, and oxycodone per 100K people and by 3-digit zip codes and overdose rates from 2014 to 2018 in California, which legalized recreational marijuana in 2016, were compared to Texas, where marijuana is functionally prohibited. Drug weights were obtained from the Automation of Reports and Consolidated Orders System and converted to oral morphine milligram equivalents. Overdose data was retrieved from the Centers for Disease Control’s WONDER database. California (−43.7%) and Texas (−27.3%) showed significant reductions in cumulative opioid distribution from 2014 to 2018. Opioid distribution per 100K people decreased −38.9% in California relative to −26.4% in Texas. Opioid and heroin overdoses increased between 1999 and 2019 by +11.6% in California but +272.7% in Texas. This evidence supports marijuana legalization as a mitigating factor to the opioid epidemic. Continued studies on safer pain management alternatives and policies will help identify measures that help combat the opioid epidemic.Competing Interest StatementDr. Brian Piper the third parties are Pfizer and Eli LillyFunding StatementThis Manuscript research was unfunded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Geisinger Institutional Review Board (GIRB)FWA # 00000063 IRB# 00008345100 N. Academy AvenueDanville, PA 17822-3069570-271-8663IRB{at}geisinger.eduAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this manuscript can be obtained online from CDC WONDER online database and the Automated Reports and Consolidated Ordering System (ARCOS) https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/ https://wonder.cdc.gov/